US stocks (^DJI, ^IXIC, ^GSPC) capped off Tuesday's session in negative territory, snapping the last two trading days' worth of gains ... and the mixed price action in commodities such as copper (HG=F ...

He explained that Tempus works with two main groups: 19 of the top 20 large pharmaceutical companies and a few hundred smaller biotechs. The CFO acknowledged that the biotech sector has felt the ...

Global copper market faces surplus due to rising production and trade tensions. ICSG projects 289,000 metric tons surplus in ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

The fund aims to deliver twice (200%) the daily performance of the common stock of Tempus AI, Inc. (Nasdaq ... of the introduction in late April of two first-to-market single-stock leveraged ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this.

BTIG just kicked off coverage on Tempus AI (NASDAQ:TEM) with a Buy rating and a $60 price target suggesting nearly 48% upside from where the stock trades now. Analyst Mark Massaro called the ...

Tempus AI announced a collaboration with AstraZeneca and Pathos AI. The deal will generate $200 million for Tempus AI in data licensing and model development fees. Tempus AI has invested heavily ...

Tempus AI (NASDAQ: TEM), a fast-rising player in clinical AI and health data infrastructure, will report its Q1 2025 earnings after the market closes today. Analysts expect revenue of $248.1 ...